Q1 2020 EPS Estimates for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Boosted by William Blair

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Stock analysts at William Blair lifted their Q1 2020 earnings estimates for shares of Biohaven Pharmaceutical in a research report issued to clients and investors on Monday, February 10th. William Blair analyst T. Lugo now expects that the company will post earnings per share of ($2.19) for the quarter, up from their prior estimate of ($2.42). William Blair has a “Buy” rating on the stock. William Blair also issued estimates for Biohaven Pharmaceutical’s Q2 2020 earnings at ($2.03) EPS, Q3 2020 earnings at ($1.87) EPS, Q4 2020 earnings at ($1.70) EPS, FY2020 earnings at ($7.79) EPS and FY2022 earnings at $2.38 EPS.

BHVN has been the subject of a number of other research reports. Goldman Sachs Group dropped their target price on Biohaven Pharmaceutical from $89.00 to $76.00 and set a “buy” rating for the company in a report on Monday, February 10th. Zacks Investment Research downgraded Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a report on Monday, January 27th. Canaccord Genuity reissued a “buy” rating and set a $80.00 target price on shares of Biohaven Pharmaceutical in a report on Tuesday. Oppenheimer downgraded Biohaven Pharmaceutical from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $67.00 to $51.00 in a report on Monday, February 10th. Finally, Cantor Fitzgerald lifted their target price on Biohaven Pharmaceutical from $87.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, October 28th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $69.23.

BHVN opened at $45.33 on Thursday. Biohaven Pharmaceutical has a fifty-two week low of $36.69 and a fifty-two week high of $67.86. The company has a market capitalization of $2.39 billion, a P/E ratio of -4.79 and a beta of 0.47. The stock has a fifty day moving average of $52.89 and a 200-day moving average of $47.82.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers grew its holdings in Biohaven Pharmaceutical by 11.7% during the third quarter. Rhumbline Advisers now owns 48,039 shares of the company’s stock worth $2,004,000 after buying an additional 5,022 shares in the last quarter. Columbus Circle Investors grew its holdings in Biohaven Pharmaceutical by 15.9% during the fourth quarter. Columbus Circle Investors now owns 23,593 shares of the company’s stock worth $1,284,000 after buying an additional 3,235 shares in the last quarter. GW&K Investment Management LLC grew its holdings in Biohaven Pharmaceutical by 41.5% during the third quarter. GW&K Investment Management LLC now owns 146,376 shares of the company’s stock worth $6,107,000 after buying an additional 42,896 shares in the last quarter. California State Teachers Retirement System grew its holdings in Biohaven Pharmaceutical by 18.9% during the third quarter. California State Teachers Retirement System now owns 60,947 shares of the company’s stock worth $2,543,000 after buying an additional 9,687 shares in the last quarter. Finally, Voya Investment Management LLC grew its holdings in Biohaven Pharmaceutical by 61.2% during the third quarter. Voya Investment Management LLC now owns 413,580 shares of the company’s stock worth $17,254,000 after buying an additional 157,079 shares in the last quarter. 92.79% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Eric Aguiar sold 2,021 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $56.48, for a total value of $114,146.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Robert Berman sold 125,000 shares of the business’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $53.22, for a total value of $6,652,500.00. Following the completion of the transaction, the insider now directly owns 125,341 shares of the company’s stock, valued at approximately $6,670,648.02. The disclosure for this sale can be found here. In the last ninety days, insiders sold 176,544 shares of company stock valued at $9,506,726. 23.90% of the stock is owned by insiders.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Read More: What are the qualifications of a portfolio manager?

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.